Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib Leukemia (2005) Most patients (more than 95%) with chronic myeloid leukemia (CML) express the BCR-ABL transcript with the b2a2 (e13a2) or b3a2 (e14a2) junctions corresponding to the major BCR gene breakpoint cluster region (M-BCR). We and others have reported that a small proportion of CML patients (1-2%), who have breakpoints that fall outside of the M-BCR in chromosome 22, give rise to a shortened BCR-ABL transcript with an e1a2 junction (m-BCR), e6a2, b2a3 (e13a3), b3a3 (e14a3) or longer BCR-ABL transcripts with an e19a2 (m-BCR) junction ( Figure 1a ). The majority of these atypical transcripts encode fusion proteins that lack or retain different BCR domains, which could influence the clinical phenotype of the disease entity. 1 The clinical and hematologic features of eight additional patients with e8a2 BCR-ABL fusions transcripts have been recently reviewed 2 and, according to the authors, could be associated with a worse prognosis than M-BCR transcripts. An inverse correlation between the size of the BCR portion retained in the fusion protein and the aggressive behavior of the disease was suggested and thus BCR domains could attenuate the leukemic phenotype. 2 In this manuscript, we report for the first time to our knowledge, three additional CML patients with an e8a2 BCR-ABL fusion transcript treated with imatinib mesylate with a median follow-up of 34 months.
These cases (patients no. 1, 2 and 3) were diagnosed with CML in chronic phase based on typical peripheral blood findings and on standard karyotyping analyses indicating t(9;22)(q34;q11). The relevant clinical and biological data for the patients are given in Table 1 . In case no. 1, fluorescence in situ hybridization (FISH) analysis performed with dual color probes for BCR and ABL genes (LSI bcr/abl ES Dual Color Translocation Probe, VYSIS Downer's Grove, IL, USA) showed a typical M-BCR picture in 20 metaphases and 100 interphase nuclei (data not shown) which was different from the case previously described. 2 The first case (no. 1), a 40-year-old male patient, was referred to the Centre Hospitalier Lyon Sud hospital showed an atypically large fragment that turned out to correspond, after direct sequencing, to an e8a2 fusion transcript with a 55 base pair (bp) insert that wholly matched an inverted sequence from ABL intron Ib ( Figure 1a ). The monitoring of the minimal residual disease (MRD) was carried out using real-time RT-PCR 3 with specific forward primers, located close to the e8-BCR (Figure 1b ). The introduction of imatinib mesylate therapy at 400 mg/day allowed complete hematologic and cytogenetic responses at 6 months and a major molecular response in all cases, with a reduction of at least three logs of BCR-ABL transcript levels compared to the diagnosis, at a median follow-up of 34 months (range 30-39) ( Figure 1b ). Of note, in cases no. 2 and no. 3, a major molecular response was obtained only after increasing the dosage of imatinib, suggesting that those patients may require higher doses (600 mg/day) of imatinib to achieve proper molecular response. Most of the previously described patients with an e8a2 BCR-ABL fusion transcript had thrombocytosis and seemed to be associated with worse prognosis.
2 None of the cases described here showed thrombocytosis (Table 1) . Moreover, none of the patients previously described, treated with interferon-a, achieved even a minor response; all of the cases treated with imatinib were alive at a median follow-up of 34 months, achieved complete cytogenetic remission at a median follow-up of 7 months and a major molecular remission (BCR-ABL/ABLo0,12%) at a median follow-up of 20 months indicating thus the efficacy of imatinib mesylate in patients with rare BCR-ABL transcripts. The aggressive clinical course of these leukemias suggested previously could be shrouded by appropriate targeted therapy. The direct junction between exons e8 from BCR gene and a2 from ABL gene would generate a stop codon. The open reading frame was preserved either by insertion of intronic sequences from ABL gene, or either (in 3/11 cases described previously) with a break inside the exon e8 from BCR gene. 2 An interesting common feature was that in all cases described here (and in three previously reported patients, 2,4,5 which accounts for more than 50% of the e8a2 patients described to date and therefore could represent the most frequent rearrangement in e8a2 patients) molecular study showed an identical 55 bp inverted fragment insertion from ABL intron Ib (Figure 1a) . It has been suggested that the presence of translisin recognition sites, ALU sequences or cryptic splice site signals in the translocation region could contribute to these complex rearrangements. [5] [6] [7] This 55 bp inverted fragment added to the two first nucleotides of exon a2 from ABL gene is capable of encoding 19 amino acids. Protein motif analysis using the PROSITE database indicated that they contain a Clathrin box motif, found on cargo adaptator proteins (amino acids 14-18, Figure 1a ). There is little information about the biological function of this protein feature, but it could be involved in endocytosis or in cooperative interaction between 3 Primers (ENF1003, EN R1063) and probe (EN P1043) from ABL control gene were used to normalize results. 3 For PCR calibration, a serial 10-fold dilution series of e8a2 cDNA from the sample before imatinib mesylate therapy (ranging from 10 6 to 10 1 copies) was amplified and the assay was found to be linear over at least five orders of magnitude (case no. 1: slope À3.47, intercept 40.8; case no. 2 and no. 3: slope À3.53, intercept 41). The final results were calculated as ratios BCR-ABL/ABL.
SPOTLIGHT
Spotlight Correspondence proteins in vesicular trafficking. 8 Obviously, structure/function studies would bring a more comprehensive survey on the real biological significance of this small motif insertion.
Very few patients have been reported with the unusual e8a2 BCR-ABL transcript; prediction concerning their clinical outcome or the best rational strategy to avoid progression 9 cannot yet be made even if the efficacy of imatinib mesylate therapy was confirmed in this study. A longer follow-up and the analysis of a large number of patients with e8a2 BCR-ABL fusions is absolutely necessary to take into account the clinical outcome of these patients and for proper assessment of prognosis in the presence of these rare transcripts. The study of these unusual BCR-ABL junctions and their associated disease seems to be essential to gain more insights into their molecular pathological function and a more comprehensive survey of the different functions of the BCR-ABL chimeric protein. 
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